X4 Pharmaceuticals, Inc — Director's Dealing 2017

Nov 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-15

Reporting Person: Alexandria Venture Investments, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-15	Common stock	C	225680	—	Acquired	225680	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-15	Series D convertible preferred stock	$	C	770249	Disposed		Common stock (225680.0)	Direct

Footnotes

F1: Preferred shares are convertible at a ratio of 3.413 shares of preferred stock to 1 share of common stock

F2: Not applicable